{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:22:59Z","timestamp":1793715779275,"version":"4.6.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014434","name":"Narodowa Agencja Wymiany Akademickiej","doi-asserted-by":"publisher","award":["BPN\/WAL\/2022\/1\/00007\/U\/00001"],"award-info":[{"award-number":["BPN\/WAL\/2022\/1\/00007\/U\/00001"]}],"id":[{"id":"10.13039\/501100014434","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Haworth Family Professorship in Neurodegenerative Diseases fund","award":["Haworth Family Professorship in Neurodegenerative Diseases fund"],"award-info":[{"award-number":["Haworth Family Professorship in Neurodegenerative Diseases fund"]}]},{"name":"Haworth Family Professorship in Neurodegenerative Diseases fund","award":["Haworth Family Professorship in Neurodegenerative Diseases fund"],"award-info":[{"award-number":["Haworth Family Professorship in Neurodegenerative Diseases fund"]}]},{"name":"The Albertson Parkinson\u2019s Research Foundation","award":["The Albertson Parkinson\u2019s Research Foundation"],"award-info":[{"award-number":["The Albertson Parkinson\u2019s Research Foundation"]}]},{"name":"NIH\/NIA and NIH\/NINDS","award":["1U19AG063911"],"award-info":[{"award-number":["1U19AG063911"]}]},{"DOI":"10.13039\/100014535","name":"Center for Individualized Medicine, Mayo Clinic","doi-asserted-by":"publisher","award":["Center for Individualized Medicine, Mayo Clinic"],"award-info":[{"award-number":["Center for Individualized Medicine, Mayo Clinic"]}],"id":[{"id":"10.13039\/100014535","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mayo Clinic APDA Center for Advanced Research","award":["Mayo Clinic APDA Center for Advanced Research"],"award-info":[{"award-number":["Mayo Clinic APDA Center for Advanced Research"]}]},{"name":"the gifts from the Donald G. and Jodi P. Heeringa Family","award":["the gifts from the Donald G. and Jodi P. Heeringa Family"],"award-info":[{"award-number":["the gifts from the Donald G. and Jodi P. Heeringa Family"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>CSF1R<\/jats:italic>\n                    mutations cause autosomal-dominant\n                    <jats:italic>CSF1R<\/jats:italic>\n                    -related leukoencephalopathy with axonal spheroids and pigmented glia (\n                    <jats:italic>CSF1R<\/jats:italic>\n                    -ALSP) and autosomal-recessive brain abnormalities, neurodegeneration, and dysosteosclerosis (BANDDOS). The former is increasingly recognized, and disease-modifying therapy was introduced; however, literature is scarce on the latter. This review analyzes BANDDOS and discusses similarities and differences with\n                    <jats:italic>CSF1R<\/jats:italic>\n                    -ALSP.\n                  <\/jats:p>\n                  <jats:p>\n                    We systematically retrieved and analyzed the clinical, genetic, radiological, and pathological data on the previously reported and our cases with BANDDOS. We identified 19 patients with BANDDOS (literature search according to the PRISMA 2020 guidelines: n\u2009=\u200916, our material: n\u2009=\u20093). We found 11\n                    <jats:italic>CSF1R<\/jats:italic>\n                    mutations, including splicing (n\u2009=\u20093), missense (n\u2009=\u20093), nonsense (n\u2009=\u20092), and intronic (n\u2009=\u20092) variants and one inframe deletion. All mutations disrupted the tyrosine kinase domain or resulted in nonsense-mediated mRNA decay. The material is heterogenous, and the presented information refers to the number of patients with sufficient data on specific symptoms, results, or performed procedures. The first symptoms occurred in the perinatal period (n\u2009=\u20095), infancy (n\u2009=\u20092), childhood (n\u2009=\u20095), and adulthood (n\u2009=\u20091). Dysmorphic features were present in 7\/17 cases. Neurological symptoms included speech disturbances (n\u2009=\u200913\/15), cognitive decline (n\u2009=\u200912\/14), spasticity\/rigidity (n\u2009=\u200912\/15), hyperactive tendon reflex (n\u2009=\u200911\/14), pathological reflexes (n\u2009=\u20098\/11), seizures (n\u2009=\u20099\/16), dysphagia (n\u2009=\u20099\/12), developmental delay (n\u2009=\u20097\/14), infantile hypotonia (n\u2009=\u20093\/11), and optic nerve atrophy (n\u2009=\u20092\/7). Skeletal deformities were observed in 13\/17 cases and fell within the dysosteosclerosis \u2013 Pyle disease spectrum. Brain abnormalities included white matter changes (n\u2009=\u200919\/19), calcifications (n\u2009=\u200915\/18), agenesis of corpus callosum (n\u2009=\u200912\/16), ventriculomegaly (n\u2009=\u200913\/19), Dandy-Walker complex (n\u2009=\u20097\/19), and cortical abnormalities (n\u2009=\u20094\/10). Three patients died in infancy, two in childhood, and one case at unspecified age. A single brain autopsy evidenced multiple brain anomalies, absence of corpus callosum, absence of microglia, severe white matter atrophy with axonal spheroids, gliosis, and numerous dystrophic calcifications.\n                  <\/jats:p>\n                  <jats:p>\n                    In conclusion, BANDDOS presents in the perinatal period or infancy and has a devastating course with congenital brain abnormalities, developmental delay, neurological deficits, osteopetrosis, and dysmorphic features. There is a significant overlap in the clinical, radiological, and neuropathological aspects between BANDDOS and\n                    <jats:italic>CSF1R<\/jats:italic>\n                    -ALSP. As both disorders are on the same continuum, there is a window of opportunity to apply available therapy in\n                    <jats:italic>CSF1R<\/jats:italic>\n                    -ALSP to BANDDOS.\n                  <\/jats:p>","DOI":"10.1186\/s13023-023-02772-9","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T22:15:33Z","timestamp":1687472133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Brain abnormalities, neurodegeneration, and dysosteosclerosis (BANDDOS): new cases, systematic literature review, and associations with CSF1R-ALSP"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5517-9875","authenticated-orcid":false,"given":"Jaros\u0142aw","family":"Dulski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3530-1826","authenticated-orcid":false,"given":"Josiane","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara L\u00facia","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5487-1053","authenticated-orcid":false,"given":"Zbigniew K.","family":"Wszolek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"2772_CR1","doi-asserted-by":"publisher","first-page":"788168","DOI":"10.3389\/fneur.2021.788168","volume":"12","author":"S Papapetropoulos","year":"2021","unstructured":"Papapetropoulos S, Pontius A, Finger E, Karrenbauer V, Lynch DS, Brennan M, et al. Adult-onset Leukoencephalopathy with Axonal Spheroids and pigmented glia: review of clinical manifestations as foundations for Therapeutic Development. Front Neurol. 2021;12:788168.","journal-title":"Front Neurol"},{"issue":"24","key":"2772_CR2","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1212\/WNL.0000000000006642","volume":"91","author":"T Konno","year":"2018","unstructured":"Konno T, Kasanuki K, Ikeuchi T, Dickson DW, Wszolek ZK. CSF1R-related leukoencephalopathy: a major player in primary microgliopathies. Neurology. 2018;91(24):1092\u2013104.","journal-title":"Neurology"},{"issue":"1","key":"2772_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/ene.13125","volume":"24","author":"T Konno","year":"2017","unstructured":"Konno T, Yoshida K, Mizuno T, Kawarai T, Tada M, Nozaki H, et al. Clinical and genetic characterization of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia associated with CSF1R mutation. Eur J Neurol. 2017;24(1):37\u201345.","journal-title":"Eur J Neurol"},{"issue":"1","key":"2772_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/ene.13464","volume":"25","author":"T Konno","year":"2018","unstructured":"Konno T, Yoshida K, Mizuta I, Mizuno T, Kawarai T, Tada M, et al. Diagnostic criteria for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia due to CSF1R mutation. Eur J Neurol. 2018;25(1):142\u20137.","journal-title":"Eur J Neurol"},{"issue":"22","key":"2772_CR5","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1212\/WNL.0b013e3181a826c0","volume":"72","author":"C Wider","year":"2009","unstructured":"Wider C, Van Gerpen JA, DeArmond S, Shuster EA, Dickson DW, Wszolek ZK. Leukoencephalopathy with spheroids (HDLS) and pigmentary leukodystrophy (POLD): a single entity? Neurology. 2009;72(22):1953\u20139.","journal-title":"Neurology"},{"issue":"6","key":"2772_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00401-004-0847-x","volume":"107","author":"JD Marotti","year":"2004","unstructured":"Marotti JD, Tobias S, Fratkin JD, Powers JM, Rhodes CH. Adult onset leukodystrophy with neuroaxonal spheroids and pigmented glia: report of a family, historical perspective, and review of the literature. Acta Neuropathol. 2004;107(6):481\u20138.","journal-title":"Acta Neuropathol"},{"issue":"12","key":"2772_CR7","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jamaneurol.2016.2229","volume":"73","author":"DS Lynch","year":"2016","unstructured":"Lynch DS, Zhang WJ, Lakshmanan R, Kinsella JA, Uzun GA, Karbay M, et al. Analysis of mutations in AARS2 in a series of CSF1R-Negative patients with adult-onset Leukoencephalopathy with Axonal Spheroids and pigmented glia. JAMA Neurol. 2016;73(12):1433\u20139.","journal-title":"JAMA Neurol"},{"issue":"1","key":"2772_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s40478-019-0843-y","volume":"7","author":"C Sundal","year":"2019","unstructured":"Sundal C, Carmona S, Yhr M, Almstr\u00f6m O, Ljungberg M, Hardy J, et al. An AARS variant as the likely cause of swedish type hereditary diffuse leukoencephalopathy with spheroids. Acta Neuropathol Commun. 2019;7(1):188.","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"2772_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/mdc3.13650","volume":"10","author":"J Dulski","year":"2023","unstructured":"Dulski J, Koga S, Dickson DW, Wszolek ZK. Report of A Family with Adult-Onset Leukoencephalopathy with Axonal Spheroids and pigmented glia (ALSP) without mutations in CSF1R, AARS1 or AARS2. Mov Disord Clin Pract. 2023;10(2):307\u201312.","journal-title":"Mov Disord Clin Pract"},{"issue":"5","key":"2772_CR10","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ajhg.2019.03.004","volume":"104","author":"L Guo","year":"2019","unstructured":"Guo L, Bertola DR, Takanohashi A, Saito A, Segawa Y, Yokota T, et al. Bi-allelic CSF1R mutations cause skeletal dysplasia of dysosteosclerosis-pyle Disease Spectrum and degenerative encephalopathy with Brain Malformation. Am J Hum Genet. 2019;104(5):925\u201335.","journal-title":"Am J Hum Genet"},{"key":"2772_CR11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"5","key":"2772_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"},{"issue":"10","key":"2772_CR13","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/gim.2017.22","volume":"19","author":"D Monies","year":"2017","unstructured":"Monies D, Maddirevula S, Kurdi W, Alanazy MH, Alkhalidi H, Al-Owain M, et al. Autozygosity reveals recessive mutations and novel mechanisms in dominant genes: implications in variant interpretation. Genet Med. 2017;19(10):1144\u201350.","journal-title":"Genet Med"},{"issue":"5","key":"2772_CR14","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.ajhg.2019.03.010","volume":"104","author":"N Oosterhof","year":"2019","unstructured":"Oosterhof N, Chang IJ, Karimiani EG, Kuil LE, Jensen DM, Daza R, et al. Homozygous mutations in CSF1R cause a Pediatric-Onset Leukoencephalopathy and can result in congenital absence of Microglia. Am J Hum Genet. 2019;104(5):936\u201347.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"2772_CR15","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/ajmg.a.62179","volume":"185","author":"E K\u0131nd\u0131\u015f","year":"2021","unstructured":"K\u0131nd\u0131\u015f E, Simsek-Kiper P, Ko\u015fukcu C, Ta\u015fk\u0131ran EZ, G\u00f6\u00e7men R, Utine E, et al. Further expanding the mutational spectrum of brain abnormalities, neurodegeneration, and dysosteosclerosis: a rare disorder with neurologic regression and skeletal features. Am J Med Genet Part A. 2021;185(6):1888\u201396.","journal-title":"Am J Med Genet Part A"},{"issue":"4","key":"2772_CR16","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1055\/s-0040-1702161","volume":"51","author":"PM Tamhankar","year":"2020","unstructured":"Tamhankar PM, Zhu B, Tamhankar VP, Mithbawkar S, Seabra L, Livingston JH, et al. A Novel Hypomorphic CSF1R Gene Mutation in the biallelic state leading to fatal Childhood Neurodegeneration. Neuropediatrics. 2020;51(4):302\u20136.","journal-title":"Neuropediatrics"},{"issue":"1","key":"2772_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/acn3.50957","volume":"7","author":"G Helman","year":"2020","unstructured":"Helman G, Lajoie BR, Crawford J, Takanohashi A, Walkiewicz M, Dolzhenko E, et al. Genome sequencing in persistently unsolved white matter disorders. Ann Clin Transl Neurol. 2020;7(1):144\u201352.","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"2772_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/joim.13420","volume":"291","author":"GC Mickeviciute","year":"2022","unstructured":"Mickeviciute GC, Valiuskyte M, Platt\u00e9n M, Wszolek ZK, Andersen O, Danylait\u00e9 Karrenbauer V, et al. Neuroimaging phenotypes of CSF1R-related leukoencephalopathy: systematic review, meta-analysis, and imaging recommendations. J Intern Med. 2022;291(3):269\u201382.","journal-title":"J Intern Med"},{"key":"2772_CR19","doi-asserted-by":"crossref","unstructured":"Dulski J, Middlebrooks EH, Wszolek ZK. Novel Application of 7T MRI in CSF1R-Related Leukoencephalopathy. Neurology. 2022.","DOI":"10.1212\/WNL.0000000000201450"},{"issue":"1","key":"2772_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s13023-022-02501-8","volume":"17","author":"C Sevin","year":"2022","unstructured":"Sevin C, Barth M, Wilds A, Afriyie A, Walz M, Dillon A, et al. An international study of caregiver-reported burden and quality of life in metachromatic leukodystrophy. Orphanet J Rare Dis. 2022;17(1):329.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2772_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13023-021-01828-y","volume":"16","author":"L Ammann-Schnell","year":"2021","unstructured":"Ammann-Schnell L, Groeschel S, Kehrer C, Fr\u00f6lich S, Kr\u00e4geloh-Mann I. The impact of severe rare chronic neurological disease in childhood on the quality of life of families-a study on MLD and PCH2. Orphanet J Rare Dis. 2021;16(1):211.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2772_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13023-020-01596-1","volume":"16","author":"CS Corre","year":"2021","unstructured":"Corre CS, Grant N, Sadjadi R, Hayden D, Becker C, Gomery P, et al. Beyond gait and balance: urinary and bowel dysfunction in X-linked adrenoleukodystrophy. Orphanet J Rare Dis. 2021;16(1):14.","journal-title":"Orphanet J Rare Dis"},{"issue":"D1","key":"2772_CR23","doi-asserted-by":"publisher","first-page":"D523","DOI":"10.1093\/nar\/gkac1052","volume":"51","author":"The UniProt C","year":"2023","unstructured":"The UniProt C. UniProt: the Universal protein knowledgebase in 2023. Nucleic Acids Res. 2023;51(D1):D523\u2013D31.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"2772_CR24","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/glia.23980","volume":"69","author":"DE Marzan","year":"2021","unstructured":"Marzan DE, Br\u00fcgger-Verdon V, West BL, Liddelow S, Samanta J, Salzer JL. Activated microglia drive demyelination via CSF1R signaling. Glia. 2021;69(6):1583\u2013604.","journal-title":"Glia"},{"issue":"9","key":"2772_CR25","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1016\/j.celrep.2020.02.028","volume":"30","author":"V Chitu","year":"2020","unstructured":"Chitu V, Biundo F, Shlager GGL, Park ES, Wang P, Gulinello ME, et al. Microglial homeostasis requires balanced CSF-1\/CSF-2 receptor signaling. Cell Rep. 2020;30(9):3004\u201319e5.","journal-title":"Cell Rep"},{"issue":"3","key":"2772_CR26","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/glia.23929","volume":"69","author":"F Biundo","year":"2021","unstructured":"Biundo F, Chitu V, Shlager GGL, Park ES, Gulinello ME, Saha K, et al. Microglial reduction of colony stimulating factor-1 receptor expression is sufficient to confer adult onset leukodystrophy. Glia. 2021;69(3):779\u201391.","journal-title":"Glia"},{"issue":"2","key":"2772_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/ng.1027","volume":"44","author":"R Rademakers","year":"2011","unstructured":"Rademakers R, Baker M, Nicholson AM, Rutherford NJ, Finch N, Soto-Ortolaza A, et al. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet. 2011;44(2):200\u20135.","journal-title":"Nat Genet"},{"issue":"1","key":"2772_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/ene.15115","volume":"29","author":"X Ayrignac","year":"2022","unstructured":"Ayrignac X, Carra-Dalli\u00e8re C, Codjia P, Mouzat K, Castelnovo G, Ellie E, et al. Evaluation of CSF1R-related adult onset leukoencephalopathy with axonal spheroids and pigmented glia diagnostic criteria. Eur J Neurol. 2022;29(1):329\u201334.","journal-title":"Eur J Neurol"},{"issue":"9","key":"2772_CR29","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.3174\/ajnr.A5744","volume":"39","author":"P Codjia","year":"2018","unstructured":"Codjia P, Ayrignac X, Mochel F, Mouzat K, Carra-Dalliere C, Castelnovo G, et al. Adult-onset Leukoencephalopathy with Axonal Spheroids and pigmented glia: an MRI study of 16 french cases. AJNR Am J Neuroradiol. 2018;39(9):1657\u201361.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"6","key":"2772_CR30","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/ene.13611","volume":"25","author":"T Konno","year":"2018","unstructured":"Konno T, Miura T, Harriott AM, Mezaki N, Edwards ES, Rademakers R, et al. Partial loss of function of colony-stimulating factor 1 receptor in a patient with white matter abnormalities. Eur J Neurol. 2018;25(6):875\u201381.","journal-title":"Eur J Neurol"},{"issue":"3","key":"2772_CR31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.5603\/PJNNS.a2021.0022","volume":"55","author":"ZK Wszolek","year":"2021","unstructured":"Wszolek ZK. First polish case of CSF1R-related leukoencephalopathy. Neurol Neurochir Pol. 2021;55(3):239\u201340.","journal-title":"Neurol Neurochir Pol"},{"issue":"3","key":"2772_CR32","doi-asserted-by":"publisher","first-page":"322","DOI":"10.5603\/PJNNS.a2021.0012","volume":"55","author":"K \u017bur-Wyrozumska","year":"2021","unstructured":"\u017bur-Wyrozumska K, Kaczmarska P, Mensah-Glanowska P. Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia associated with an A792D mutation in the CSF1R gene in a polish patient. Neurol Neurochir Pol. 2021;55(3):322\u20134.","journal-title":"Neurol Neurochir Pol"},{"key":"2772_CR33","doi-asserted-by":"crossref","unstructured":"Dulski J, Heckman MG, White LJ, \u017bur-Wyrozumska K, Lund TC, Wszolek ZK. Hematopoietic stem cell transplantation in CSF1R-Related Leukoencephalopathy: retrospective study on predictors of outcomes. Pharmaceutics. 2022;14(12).","DOI":"10.3390\/pharmaceutics14122778"},{"issue":"12","key":"2772_CR34","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1002\/mds.28734","volume":"36","author":"PW Tipton","year":"2021","unstructured":"Tipton PW, Kenney-Jung D, Rush BK, Middlebrooks EH, Nascene D, Singh B, et al. Treatment of CSF1R-Related Leukoencephalopathy: breaking New Ground. Mov Disord. 2021;36(12):2901\u20139.","journal-title":"Mov Disord"},{"issue":"4","key":"2772_CR35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00018-022-04225-1","volume":"79","author":"J Han","year":"2022","unstructured":"Han J, Chitu V, Stanley ER, Wszolek ZK, Karrenbauer VD, Harris RA. Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges. Cell Mol Life Sci. 2022;79(4):219.","journal-title":"Cell Mol Life Sci"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02772-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02772-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02772-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T22:20:03Z","timestamp":1687472403000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02772-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2772"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02772-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"assertion":[{"value":"6 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The information on the newly reported 3 patients was collected under the approval of the local Institutional Review Boards. The information on the remaining 17 patients was collected through the literature review, and IRB consent was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval statement"}},{"value":"Informed consent was obtained from the newly reported 3 cases.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Jaroslaw Dulski:Stock Ownership in medically-related fields: none.Intellectual Property Rights: none.Consultancies: none.Expert Testimony: none.Advisory Boards: none.Employment: Medical University of Gdansk, Copernicus PL Ltd., MJ Jaros\u0142aw Dulski.Partnerships: none.Contracts: none.Honoraria: VM Media Ltd., Rados\u0142aw Lipi\u0144ski 90 Consulting, Ipsen.Royalties: none.Grants: Polish National Agency for Academic Exchange (BPN\/WAL\/2022\/1\/00007\/U\/00001), the Haworth Family Professorship in Neurodegenerative Diseases fund.Other: none.Josiane Souza.Stock Ownership in medically-related fields: none.Intellectual Property Rights: none.Consultancies: none.Expert Testimony: none.Advisory Boards: none.Employment: Hospital Pequeno Pricnipe; Medical University of PUCPR; Federal Medical Expert in the Ministry of Social Security; Curitiba, Paran\u00e1, Brazil.Partnerships: none.Contracts: none.Honoraria: none.Royalties: none.Grants: none.Other: none.Mara L\u00facia Santos.Stock Ownership in medically-related fields: none.Intellectual Property Rights: none.Consultancies: none.Expert Testimony: none.Advisory Boards: none.Employment: Hospital Pequeno Pricnipe;Partnerships: none.Contracts: none.Honoraria: none.Royalties: none.Grants: none.Other: none.Zbigniew K. Wszolek:\u00a0ZKW is partially supported by the NIH\/NIA and NIH\/NINDS (1U19AG063911, FAIN: U19AG063911), Mayo Clinic Center for Regenerative Medicine, the gifts from the Donald G. and Jodi P. Heeringa Family, the Haworth Family Professorship in Neurodegenerative Diseases fund, and The Albertson Parkinson\u2019s Research Foundation. He serves as PI or Co-PI on Biohaven Pharmaceuticals, Inc. (BHV4157-206) and Vigil Neuroscience, Inc. (VGL101-01.002, VGL101-01.201, PET tracer development protocol, Csf1r biomarker and repository project, and ultra-high field MRI in the diagnosis and management of CSF1R-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia) projects\/grants. He serves as Co-PI of the Mayo Clinic APDA Center for Advanced Research and as an external advisory board member for the Vigil Neuroscience, Inc., and as a consultant on neurodegenerative medical research for Eli Lilli & Company.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Detailed disclosures"}},{"value":"was collected from the parents of the three newly reported Brazilian cases.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"160"}}